Allison Anastasoff
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 29.4% of the total. Reporting peaked in 2024 at $1,135 and has fallen 69.4% since, to $347 in 2025. Among family clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$656
- Ironwood Pharmaceuticals, Inc$477
- Takeda Pharmaceuticals U.S.A., Inc.$291
- Gilead$281
- Pfizer$184
- plus $839 from 14 others
What the payments were for
- Food & beverage$3,851100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $1,135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $656 |
| Ironwood Pharmaceuticals, Inc | 22 | $477 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $291 |
| Gilead | 11 | $281 |
| Pfizer | 8 | $184 |
| Johnson & Johnson | 9 | $171 |
| Bristol Myers Squibb | 7 | $145 |
| Phathom Pharmaceuticals, Inc. | 6 | $126 |
| Sanofi | 4 | $98 |
| E.r. Squibb & Sons, L.L.C. | 1 | $85 |
| QOL Medical, LLC | 2 | $47 |
| Merck | 1 | $28 |
| Braintree Laboratories, Inc. | 1 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Ardelyx, Inc. | 1 | $20 |
| Organon | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $17 |
| Medtronic | 1 | $13 |
How this compares
$3,862 in reported general payments places this provider in the 95th percentile of 713 family providers in New Hampshire.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 24 | $26,549 |
| Omeprazole | 207 | $3,914 |
| Pantoprazole Sodium | 186 | $2,946 |
| Famotidine | 59 | $1,065 |
| Esomeprazole Magnesium | 14 | $506 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 23 | $340 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $171 |
| Ondansetron OdtOndansetron | 19 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,135 | $26,54924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 713 family providers in New Hampshire.
Other family in Derry
- Summer BellDerry$16K
- Lauren AbbottDerry$6K
- Jan LevesqueDerry$3K
- Jenna ClarkDerry$3K
- Tara Delle ChiaieHampton$548K
- Wendy WrightAmherst$447K
- Richard CareyNashua$51K
- Laura HudsonDover$14K
- Debra KrisonNorth Hampton$13K
- Michelle WhiteBedford$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.